Dear Doctor Letter (Rote-Hand-Brief) on Xalkori® (crizotinib): New recommendations regarding the risk of cardiac insufficiency
2015.10.14
Active substance: crizotinib
The company Pfizer Pharma GmbH is circulating information that severe, sometimes lethal, cases of cardiac insufficiency have been reported in patients with ALK-positive NSCLC treated with crizotinib.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN